{
    "PMC8668943_3": [
        {
            "subject": {
                "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                "adjustment factors": "birthweight and FCGR2C genotypes",
                "group": "Total group",
                "Fc\u03b3RIIc copy number": "1 copy",
                "statistical measure": "Univariate OR",
                "confidence interval": "95% CI",
                "value": "0.29 (0.12-0.71)",
                "P-value": "0.007",
                "Bonferroni corrected P-value": "0.112"
            },
            "measures": "[Univariate OR, P-value]",
            "outcomes": "[0.29 (0.12-0.71), 0.007]"
        },
        {
            "subject": {
                "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                "adjustment factors": "birthweight and FCGR2C genotypes",
                "group": "Total group",
                "Fc\u03b3RIIc copy number": "1 copy",
                "statistical measure": "Adjusted OR",
                "confidence interval": "95% CI",
                "value": "0.37 (0.15-0.90)",
                "P-value": "0.029",
                "Bonferroni corrected P-value": "0.464"
            },
            "measures": "[Adjusted OR, P-value]",
            "outcomes": "[0.37 (0.15-0.90), 0.029]"
        },
        {
            "subject": {
                "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                "adjustment factors": "birthweight and FCGR2C genotypes",
                "group": "Total group",
                "Fc\u03b3RIIc copy number": "2 copies",
                "statistical measure": "Adjusted OR",
                "value": "Ref"
            }
        },
        {
            "subject": {
                "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                "adjustment factors": "birthweight and FCGR2C genotypes",
                "group": "Total group",
                "Fc\u03b3RIIc copy number": "\u22653 copies",
                "statistical measure": "Univariate OR",
                "confidence interval": "95% CI",
                "value": "0.99 (0.63-1.57)",
                "P-value": "0.978"
            },
            "measures": "[Univariate OR, P-value]",
            "outcomes": "[0.99 (0.63-1.57), 0.978]"
        },
        {
            "subject": {
                "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                "adjustment factors": "birthweight and FCGR2C genotypes",
                "group": "Total group",
                "Fc\u03b3RIIc copy number": "\u22653 copies",
                "statistical measure": "Adjusted OR",
                "confidence interval": "95% CI",
                "value": "0.74 (0.43-1.27)",
                "P-value": "0.275"
            },
            "measures": "[Adjusted OR, P-value]",
            "outcomes": "[0.74 (0.43-1.27), 0.275]"
        }
    ],
    "PMC5817808_2": [
        {
            "subject": {
                "analysis": "survival at 24 months",
                "population": "HIV exposed infants",
                "program": "Essos hospital center PMTCT program",
                "mode of feeding": "Exclusive replacement feeding",
                "hazard ratio type": "Unadjusted",
                "HR": "Ref",
                "p-value": "Ref"
            }
        },
        {
            "subject": {
                "analysis": "survival at 24 months",
                "population": "HIV exposed infants",
                "program": "Essos hospital center PMTCT program",
                "mode of feeding": "Exclusive replacement feeding",
                "hazard ratio type": "Adjusted",
                "HR": "Ref",
                "p-value": "Ref"
            }
        },
        {
            "subject": {
                "analysis": "survival at 24 months",
                "population": "HIV exposed infants",
                "program": "Essos hospital center PMTCT program",
                "HIV status": "Negative",
                "hazard ratio type": "Unadjusted",
                "HR": "Ref",
                "p-value": "Ref"
            }
        },
        {
            "subject": {
                "analysis": "survival at 24 months",
                "population": "HIV exposed infants",
                "program": "Essos hospital center PMTCT program",
                "HIV status": "Negative",
                "hazard ratio type": "Adjusted",
                "HR": "Ref",
                "p-value": "Ref"
            }
        },
        {
            "subject": {
                "analysis": "survival at 24 months",
                "population": "HIV exposed infants",
                "program": "Essos hospital center PMTCT program",
                "birth weight": "<2500 g",
                "hazard ratio type": "Unadjusted",
                "HR": "Ref",
                "p-value": "Ref"
            }
        },
        {
            "subject": {
                "analysis": "survival at 24 months",
                "population": "HIV exposed infants",
                "program": "Essos hospital center PMTCT program",
                "birth weight": "<2500 g",
                "hazard ratio type": "Adjusted",
                "HR": "Ref",
                "p-value": "Ref"
            }
        },
        {
            "subject": {
                "analysis": "survival at 24 months",
                "population": "HIV exposed infants",
                "program": "Essos hospital center PMTCT program",
                "test": "Global Schoenfeld residuals test",
                "p-value": "0.23"
            }
        }
    ],
    "PMC5574138_3": [
        {
            "subject": {
                "analysis": "meta-regression",
                "dependent variable": "study",
                "independent variable": "length of follow-up",
                "estimate": "-0.0138",
                "standard error": "0.0666",
                "confidence interval": "(-0.1322\u20130.1046)",
                "model covariates": "length of follow-up, median CD4 cell counts, median age, year of publication, proportion of female"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "analysis": "meta-regression",
                "dependent variable": "study",
                "independent variable": "median CD4 count",
                "estimate": "-0.0034",
                "standard error": "0.0066",
                "confidence interval": "(-0.0150\u20130.0079)",
                "model covariates": "length of follow-up, median CD4 cell counts, median age, year of publication, proportion of female"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "analysis": "meta-regression",
                "dependent variable": "study",
                "independent variable": "median age",
                "estimate": "0.0415",
                "standard error": "0.0503",
                "confidence interval": "(-0.1013\u20130.0755)",
                "model covariates": "length of follow-up, median CD4 cell counts, median age, year of publication, proportion of female"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "analysis": "meta-regression",
                "dependent variable": "study",
                "independent variable": "year of publication",
                "estimate": "0.0637",
                "standard error": "0.0815",
                "confidence interval": "(-0.1736\u20130.0980)",
                "model covariates": "length of follow-up, median CD4 cell counts, median age, year of publication, proportion of female"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "analysis": "meta-regression",
                "dependent variable": "study",
                "independent variable": "female proportion",
                "estimate": "-0.5305",
                "standard error": "1.4575",
                "confidence interval": "(-3.6792\u20132.6183)",
                "model covariates": "length of follow-up, median CD4 cell counts, median age, year of publication, proportion of female"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        }
    ],
    "PMC4794224_2": [
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR2DL1",
                "frequency": "97%",
                "N": "966",
                "representation": "N (% Positive)"
            }
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR2DL3",
                "frequency": "72%",
                "N": "719",
                "representation": "N (% Positive)"
            }
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR2DL4",
                "frequency": "100%",
                "N": "993",
                "representation": "N (% Positive)"
            }
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR2DL5",
                "frequency": "55%",
                "N": "547",
                "representation": "N (% Positive)"
            }
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR2DL2*004",
                "frequency": "3%",
                "N": "31",
                "representation": "N (% Positive)"
            }
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR2DL2*001/2/3/5",
                "frequency": "55%",
                "N": "544",
                "representation": "N (% Positive)"
            }
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR2DP1",
                "frequency": "97%",
                "N": "964",
                "representation": "N (% Positive)"
            }
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR2DS1",
                "frequency": "55%",
                "N": "548",
                "representation": "N (% Positive)"
            }
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR2DS2",
                "frequency": "59%",
                "N": "581",
                "representation": "N (% Positive)"
            }
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR2DS3",
                "frequency": "40%",
                "N": "401",
                "representation": "N (% Positive)"
            }
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR2DS4",
                "frequency": "100%",
                "N": "993",
                "representation": "N (% Positive)"
            }
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR2DS5",
                "frequency": "28%",
                "N": "281",
                "representation": "N (% Positive)"
            }
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR3DL1",
                "frequency": "94%",
                "N": "929",
                "representation": "N (% Positive)"
            }
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR3DL2",
                "frequency": "100%",
                "N": "993",
                "representation": "N (% Positive)"
            }
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR3DL3",
                "frequency": "100%",
                "N": "993",
                "representation": "N (% Positive)"
            }
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "allele": "KIR3DS1",
                "frequency": "36%",
                "N": "354",
                "representation": "N (% Positive)"
            }
        }
    ],
    "PMC9077443_2": [
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Overall",
                "events per total PY in cabotegravir group": "4/1956 (0.20%)",
                "events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                "HR (hazard ratio)": "0.12 (0.05\u20130.31)",
                "p value": "<0.0001",
                "method": "Firth's method used for subgroup analysis",
                "comparison": "cabotegravir versus TDF-FTC",
                "definition": "primary endpoint",
                "analysis type": "ITT analysis",
                "PY": "person-years"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.12 (0.05\u20130.31), <0.0001]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Age",
                "subgroup": "<25 years",
                "events per total PY in cabotegravir group": "3/866 (0.35%)",
                "events per total PY in TDF-FTC group": "20/851 (2.34%)",
                "HR (hazard ratio)": "0.17 (0.05\u20130.54)",
                "comparison": "cabotegravir versus TDF-FTC",
                "definition": "primary endpoint",
                "analysis type": "ITT analysis",
                "PY": "person-years"
            },
            "measures": "[HR]",
            "outcomes": "[0.17 (0.05\u20130.54)]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Age",
                "subgroup": "\u226525 years",
                "events per total PY in cabotegravir group": "1/1090 (0.09%)",
                "events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                "HR (hazard ratio)": "0.09 (0.02\u20130.49)",
                "comparison": "cabotegravir versus TDF-FTC",
                "definition": "primary endpoint",
                "analysis type": "ITT analysis",
                "PY": "person-years"
            },
            "measures": "[HR]",
            "outcomes": "[0.09 (0.02\u20130.49)]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Contraceptive method",
                "subgroup": "DMPA",
                "events per total PY in cabotegravir group": "3/1009 (0.30%)",
                "events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                "HR (hazard ratio)": "0.16 (0.05\u20130.53)",
                "comparison": "cabotegravir versus TDF-FTC",
                "definition": "primary endpoint",
                "analysis type": "ITT analysis",
                "PY": "person-years"
            },
            "measures": "[HR]",
            "outcomes": "[0.16 (0.05\u20130.53)]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Contraceptive method",
                "subgroup": "NET-EN",
                "events per total PY in cabotegravir group": "1/175 (0.57%)",
                "events per total PY in TDF-FTC group": "6/182 (3.30%)",
                "HR (hazard ratio)": "0.22 (0.03\u20131.48)",
                "comparison": "cabotegravir versus TDF-FTC",
                "definition": "primary endpoint",
                "analysis type": "ITT analysis",
                "PY": "person-years"
            },
            "measures": "[HR]",
            "outcomes": "[0.22 (0.03\u20131.48)]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Contraceptive method",
                "subgroup": "Implant",
                "events per total PY in cabotegravir group": "0",
                "events per total PY in TDF-FTC group": "8/607 (1.32%)",
                "HR (hazard ratio)": "0.06 (0.00\u20131.16)",
                "comparison": "cabotegravir versus TDF-FTC",
                "definition": "primary endpoint",
                "analysis type": "ITT analysis",
                "PY": "person-years"
            },
            "measures": "[HR]",
            "outcomes": "[0.06 (0.00\u20131.16)]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Contraceptive method",
                "subgroup": "Other",
                "events per total PY in cabotegravir group": "0",
                "events per total PY in TDF-FTC group": "1/152 (0.66%)",
                "HR (hazard ratio)": "0.32 (0.01\u20139.89)",
                "comparison": "cabotegravir versus TDF-FTC",
                "definition": "primary endpoint",
                "analysis type": "ITT analysis",
                "PY": "person-years"
            },
            "measures": "[HR]",
            "outcomes": "[0.32 (0.01\u20139.89)]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Body-mass index",
                "subgroup": "\u226430 kg/m^2",
                "events per total PY in cabotegravir group": "4/1389 (0.29%)",
                "events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                "HR (hazard ratio)": "0.16 (0.06\u20130.45)",
                "comparison": "cabotegravir versus TDF-FTC",
                "definition": "primary endpoint",
                "analysis type": "ITT analysis",
                "PY": "person-years"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.16 (0.06\u20130.45), 0.47]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Body-mass index",
                "subgroup": ">30 kg/m^2",
                "events per total PY in cabotegravir group": "0",
                "events per total PY in TDF-FTC group": "9/495 (1.82%)",
                "HR (hazard ratio)": "0.05 (0.00\u20130.96)",
                "comparison": "cabotegravir versus TDF-FTC",
                "definition": "primary endpoint",
                "analysis type": "ITT analysis",
                "PY": "person-years"
            },
            "measures": "[HR]",
            "outcomes": "[0.05 (0.00\u20130.96)]"
        }
    ],
    "PMC10294491_2": [
        {
            "subject": {
                "trial": "DISCOVER trial",
                "analysis type": "original analysis on rate ratio scale",
                "group": "TDF/FTC",
                "number of subjects": "2693",
                "PYFU (person-years of follow-up)": "4386",
                "incident HIV infections": "11",
                "incidence rate (per 100 PYFU)": "0.251",
                "rate ratio (95% CI)": "REF"
            },
            "measures": "[metric, outcome]",
            "outcomes": ""
        },
        {
            "subject": {
                "trial": "DISCOVER trial",
                "analysis type": "original analysis on rate ratio scale",
                "group": "TAF/FTC",
                "number of subjects": "2694",
                "PYFU (person-years of follow-up)": "4370",
                "incident HIV infections": "6",
                "incidence rate (per 100 PYFU)": "0.137",
                "rate ratio (95% CI)": "0.55 (0.20, 1.48)"
            },
            "measures": "[metric, outcome]",
            "outcomes": ""
        },
        {
            "subject": {
                "trial": "DISCOVER trial",
                "analysis type": "re-analysis using an averted infections framework",
                "group": "TDF/FTC",
                "PYFU (person-years of follow-up)": "4386",
                "observed infections": "11",
                "predicted infections": "90.4",
                "averted infections": "79.4",
                "averted infections ratio (95% CI)": "REF",
                "counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                "credibility limit": "lower 2.5%"
            },
            "measures": "[metric, outcome]",
            "outcomes": ""
        },
        {
            "subject": {
                "trial": "DISCOVER trial",
                "analysis type": "re-analysis using an averted infections framework",
                "group": "TAF/FTC",
                "PYFU (person-years of follow-up)": "4370",
                "observed infections": "6",
                "predicted infections": "90.0",
                "averted infections": "84.0",
                "averted infections ratio (95% CI)": "1.06 (0.96\u20131.17)",
                "counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                "credibility limit": "lower 2.5%"
            },
            "measures": "[metric, outcome]",
            "outcomes": ""
        }
    ],
    "PMC6158807_3": [
        {
            "subject": {
                "analysis": "Number of composite endpoint events with CD4/CD8 ratio",
                "endpoint": "Composite endpoint (n = 692)",
                "number of events": "123",
                "person-year of follow-up": "4071",
                "rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "statistical test": "long rank test",
                "p-value": "< 0.001"
            },
            "measures": "[rate per 100 person-year]",
            "outcomes": "[3.02 (2.53\u20133.61)]"
        },
        {
            "subject": {
                "analysis": "Number of composite endpoint events with CD4/CD8 ratio",
                "endpoint": "Current CD4/CD8 ratio",
                "group": "< 0.3",
                "number of events": "21",
                "person-year of follow-up": "184",
                "rate per 100 person-year": "95% CI, 11.42 (7.45\u201317.52)",
                "statistical test": "long rank test",
                "p-value": "< 0.001"
            },
            "measures": "[rate per 100 person-year]",
            "outcomes": "[11.42 (7.45\u201317.52)]"
        },
        {
            "subject": {
                "analysis": "Number of composite endpoint events with CD4/CD8 ratio",
                "endpoint": "Current CD4/CD8 ratio",
                "group": "0.30\u20130.45",
                "number of events": "28",
                "person-year of follow-up": "496",
                "rate per 100 person-year": "95% CI, 5.64 (3.90\u20138.17)",
                "statistical test": "long rank test",
                "p-value": "< 0.001"
            },
            "measures": "[rate per 100 person-year]",
            "outcomes": "[5.64 (3.90\u20138.17)]"
        },
        {
            "subject": {
                "analysis": "Number of composite endpoint events with CD4/CD8 ratio",
                "endpoint": "Current CD4/CD8 ratio",
                "group": "> 0.45",
                "number of events": "72",
                "person-year of follow-up": "3227",
                "rate per 100 person-year": "95% CI, 2.23 (1.77\u20132.81)",
                "statistical test": "long rank test",
                "p-value": "< 0.001"
            },
            "measures": "[rate per 100 person-year]",
            "outcomes": "[2.23 (1.77\u20132.81)]"
        }
    ],
    "PMC7522205_2": [
        {
            "subject": {
                "analysis": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                "context": "newly diagnosed HIV patients",
                "group": "Total",
                "patients": "2845 (100.0)",
                "CD4+ median (IQR)": "160 (49\u2013310)"
            }
        },
        {
            "subject": {
                "analysis": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                "context": "newly diagnosed HIV patients",
                "group": "CRF01_AE",
                "patients": "1687 (59.3)",
                "CD4+ median (IQR)": "111 (31\u2013279)",
                "unadjusted coefficient": "0",
                "adjusted coefficient": "0"
            }
        },
        {
            "subject": {
                "analysis": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                "context": "newly diagnosed HIV patients",
                "group": "CRF07_BC",
                "patients": "254 (8.9)",
                "CD4+ median (IQR)": "250 (156\u2013377)",
                "unadjusted coefficient": "139",
                "unadjusted 95% CI": "(117\u2013161)",
                "unadjusted P": "<0.001",
                "adjusted coefficient": "113",
                "adjusted 95% CI": "(86\u2013140)",
                "adjusted P": "<0.001"
            },
            "measures": "[unadjusted coefficient, unadjusted 95% CI, unadjusted P]",
            "outcomes": [
                "[139, (117\u2013161), <0.001]",
                "[adjusted coefficient, adjusted 95% CI, adjusted P]",
                "[113, (86\u2013140), <0.001]"
            ]
        },
        {
            "subject": {
                "analysis": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                "context": "newly diagnosed HIV patients",
                "group": "CRF08_BC",
                "patients": "728 (25.6)",
                "CD4+ median (IQR)": "205 (108\u2013327)",
                "unadjusted coefficient": "94",
                "unadjusted 95% CI": "(73\u2013115)",
                "unadjusted P": "<0.001",
                "adjusted coefficient": "80",
                "adjusted 95% CI": "(65\u201395)",
                "adjusted P": "<0.001"
            },
            "measures": "[unadjusted coefficient, unadjusted 95% CI, unadjusted P]",
            "outcomes": [
                "[94, (73\u2013115), <0.001]",
                "[adjusted coefficient, adjusted 95% CI, adjusted P]",
                "[80, (65\u201395), <0.001]"
            ]
        },
        {
            "subject": {
                "analysis": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                "context": "newly diagnosed HIV patients",
                "group": "Others",
                "patients": "176 (6.2)",
                "CD4+ median (IQR)": "198 (89\u2013355)",
                "unadjusted coefficient": "87",
                "unadjusted 95% CI": "(46\u2013128)",
                "unadjusted P": "<0.001",
                "adjusted coefficient": "72",
                "adjusted 95% CI": "(37\u2013107)",
                "adjusted P": "<0.001"
            },
            "measures": "[unadjusted coefficient, unadjusted 95% CI, unadjusted P]",
            "outcomes": [
                "[87, (46\u2013128), <0.001]",
                "[adjusted coefficient, adjusted 95% CI, adjusted P]",
                "[72, (37\u2013107), <0.001]"
            ]
        }
    ],
    "PMC7414801_2": [
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "HIV detection visit",
                "group": "As-randomized",
                "sample size": "382",
                "measure": "HIV VL",
                "percentage": "100"
            },
            "measures": "[n]",
            "outcomes": "[381]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M3",
                "group": "As-randomized",
                "sample size": "382",
                "measure": "HIV VL",
                "percentage": "30"
            },
            "measures": "[n]",
            "outcomes": "[114]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M6",
                "group": "As-randomized",
                "sample size": "382",
                "measure": "HIV VL",
                "percentage": "19"
            },
            "measures": "[n]",
            "outcomes": "[73]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M9",
                "group": "As-randomized",
                "sample size": "382",
                "measure": "HIV VL",
                "percentage": "11"
            },
            "measures": "[n]",
            "outcomes": "[43]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M12",
                "group": "As-randomized",
                "sample size": "382",
                "measure": "HIV VL",
                "percentage": "7"
            },
            "measures": "[n]",
            "outcomes": "[26]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M15",
                "group": "As-randomized",
                "sample size": "382",
                "measure": "HIV VL",
                "percentage": "4"
            },
            "measures": "[n]",
            "outcomes": "[17]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "HIV detection visit",
                "group": "As-randomized",
                "sample size": "382",
                "measure": "CD4",
                "percentage": "100"
            },
            "measures": "[n]",
            "outcomes": "[382]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M3",
                "group": "As-randomized",
                "sample size": "382",
                "measure": "CD4",
                "percentage": "30"
            },
            "measures": "[n]",
            "outcomes": "[115]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M6",
                "group": "As-randomized",
                "sample size": "382",
                "measure": "CD4",
                "percentage": "19"
            },
            "measures": "[n]",
            "outcomes": "[73]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M9",
                "group": "As-randomized",
                "sample size": "382",
                "measure": "CD4",
                "percentage": "12"
            },
            "measures": "[n]",
            "outcomes": "[44]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M12",
                "group": "As-randomized",
                "sample size": "382",
                "measure": "CD4",
                "percentage": "7"
            },
            "measures": "[n]",
            "outcomes": "[26]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M15",
                "group": "As-randomized",
                "sample size": "382",
                "measure": "CD4",
                "percentage": "4"
            },
            "measures": "[n]",
            "outcomes": "[17]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "HIV detection visit",
                "group": "Continuous use",
                "sample size": "331",
                "measure": "HIV VL",
                "percentage": "100"
            },
            "measures": "[n]",
            "outcomes": "[330]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M3",
                "group": "Continuous use",
                "sample size": "331",
                "measure": "HIV VL",
                "percentage": "30"
            },
            "measures": "[n]",
            "outcomes": "[99]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M6",
                "group": "Continuous use",
                "sample size": "331",
                "measure": "HIV VL",
                "percentage": "20"
            },
            "measures": "[n]",
            "outcomes": "[65]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M9",
                "group": "Continuous use",
                "sample size": "331",
                "measure": "HIV VL",
                "percentage": "12"
            },
            "measures": "[n]",
            "outcomes": "[40]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M12",
                "group": "Continuous use",
                "sample size": "331",
                "measure": "HIV VL",
                "percentage": "8"
            },
            "measures": "[n]",
            "outcomes": "[25]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M15",
                "group": "Continuous use",
                "sample size": "331",
                "measure": "HIV VL",
                "percentage": "4"
            },
            "measures": "[n]",
            "outcomes": "[14]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "HIV detection visit",
                "group": "Continuous use",
                "sample size": "331",
                "measure": "CD4",
                "percentage": "100"
            },
            "measures": "[n]",
            "outcomes": "[331]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M3",
                "group": "Continuous use",
                "sample size": "331",
                "measure": "CD4",
                "percentage": "30"
            },
            "measures": "[n]",
            "outcomes": "[99]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M6",
                "group": "Continuous use",
                "sample size": "331",
                "measure": "CD4",
                "percentage": "19"
            },
            "measures": "[n]",
            "outcomes": "[64]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M9",
                "group": "Continuous use",
                "sample size": "331",
                "measure": "CD4",
                "percentage": "12"
            },
            "measures": "[n]",
            "outcomes": "[40]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M12",
                "group": "Continuous use",
                "sample size": "331",
                "measure": "CD4",
                "percentage": "8"
            },
            "measures": "[n]",
            "outcomes": "[25]"
        },
        {
            "subject": {
                "summary": "HIV Seroconverter Data",
                "timepoint": "M15",
                "group": "Continuous use",
                "sample size": "331",
                "measure": "CD4",
                "percentage": "4"
            },
            "measures": "[n]",
            "outcomes": "[14]"
        }
    ],
    "PMC11437459_2": [
        {
            "subject": {
                "therapy": "Atripla",
                "approval date": "2006",
                "drug": "Efavirenz (EFV)"
            }
        },
        {
            "subject": {
                "therapy": "Complera",
                "approval date": "2011",
                "drug": "Rilpivirine (RPV)"
            }
        },
        {
            "subject": {
                "therapy": "Odefsey",
                "approval date": "2016",
                "drug": "Rilpivirine (RPV)"
            }
        },
        {
            "subject": {
                "therapy": "Stribild",
                "approval date": "2012",
                "drug": "Cobicistat (COBI)"
            }
        },
        {
            "subject": {
                "therapy": "Genvoya",
                "approval date": "2015",
                "drug": "Cobicistat (COBI)"
            }
        },
        {
            "subject": {
                "therapy": "Triumeq",
                "approval date": "2014",
                "drug": "Lamivudine (3TC)"
            }
        },
        {
            "subject": {
                "therapy": "Dovato",
                "approval date": "2019",
                "drug": "Lamivudine (3TC)"
            }
        }
    ],
    "PMC9624454_2": [
        {
            "subject": {
                "analysis": "CMV detection, high-level viremia, and median viral loads among hospitalized children",
                "group": "All children",
                "HIV exposure": "All children",
                "sample size": "1024",
                "comparison to": "None"
            },
            "measures": "[CMV viremia prevalence (%), CMV viremia \u2264 1000 IU/mL prevalence (%), log10 CMV IU/mL in viremics (median, IQR)]",
            "outcomes": "[30.7, 5.8, 2.3 (1.9\u20132.7)]"
        },
        {
            "subject": {
                "analysis": "CMV detection, high-level viremia, and median viral loads among hospitalized children",
                "group": "HIV unexposed",
                "HIV exposure": "HIV unexposed",
                "sample size": "872",
                "comparison to": "None"
            },
            "measures": "[CMV viremia prevalence (%), CMV viremia \u2264 1000 IU/mL prevalence (%), log10 CMV IU/mL in viremics (median, IQR)]",
            "outcomes": "[29.0, 5.2, 2.3 (1.9\u20132.7)]"
        },
        {
            "subject": {
                "analysis": "CMV detection, high-level viremia, and median viral loads among hospitalized children",
                "group": "HIV exposed",
                "HIV exposure": "HIV exposed",
                "sample size": "118",
                "comparison to": "HIV unexposed children",
                "statistical test for CMV viremia prevalence": "\u03c7\u00b2 test",
                "statistical test for CMV viremia \u2264 1000 IU/mL prevalence": "\u03c7\u00b2 test",
                "statistical test for CMV viral load distribution": "Wilcoxon rank-sum test"
            },
            "measures": "[CMV viremia prevalence (%), CMV viremia \u2264 1000 IU/mL prevalence (%), log10 CMV IU/mL in viremics (median, IQR)]",
            "outcomes": "[38.1, 8.5, 2.4 (2.0\u20132.9)]"
        },
        {
            "subject": {
                "analysis": "CMV detection, high-level viremia, and median viral loads among hospitalized children",
                "group": "HIV exposed uninfected",
                "HIV exposure": "HIV exposed uninfected",
                "sample size": "97",
                "comparison to": "HIV unexposed children",
                "statistical test for CMV viremia prevalence": "\u03c7\u00b2 test",
                "statistical test for CMV viremia \u2264 1000 IU/mL prevalence": "\u03c7\u00b2 test",
                "statistical test for CMV viral load distribution": "Wilcoxon rank-sum test"
            },
            "measures": "[CMV viremia prevalence (%), CMV viremia \u2264 1000 IU/mL prevalence (%), log10 CMV IU/mL in viremics (median, IQR)]",
            "outcomes": "[37.1, 6.2, 2.4 (1.9\u20132.7)]"
        },
        {
            "subject": {
                "analysis": "CMV detection, high-level viremia, and median viral loads among hospitalized children",
                "group": "HIV infected",
                "HIV exposure": "HIV infected",
                "sample size": "15",
                "comparison to": "HIV unexposed children",
                "statistical test for CMV viremia prevalence": "\u03c7\u00b2 test",
                "statistical test for CMV viremia \u2264 1000 IU/mL prevalence": "\u03c7\u00b2 test",
                "statistical test for CMV viral load distribution": "Wilcoxon rank-sum test"
            },
            "measures": "[CMV viremia prevalence (%), CMV viremia \u2264 1000 IU/mL prevalence (%), log10 CMV IU/mL in viremics (median, IQR)]",
            "outcomes": "[40.0, 20.0, 3.2 (2.6\u20135.3)]"
        },
        {
            "subject": {
                "analysis": "CMV detection, high-level viremia, and median viral loads among hospitalized children",
                "group": "HIV exposed or infected",
                "HIV exposure": "HIV exposed or infected",
                "sample size": "118",
                "comparison to": "None",
                "footnote": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown"
            },
            "measures": "[None]",
            "outcomes": "[None]"
        }
    ],
    "PMC4549947_4": [
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "executive function",
                "gender": "females",
                "statistical representation": "OR"
            },
            "measures": "[OR]",
            "outcomes": "[1.3]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "executive function",
                "gender": "males",
                "statistical representation": "OR (95% CI)",
                "confidence interval": "1.5\u20135.5",
                "p-value": "0.008"
            },
            "measures": "[OR]",
            "outcomes": "[3.5]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "executive function",
                "race/ethnicity": "Hispanics",
                "statistical representation": "OR"
            },
            "measures": "[OR]",
            "outcomes": "[2.6]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "executive function",
                "race/ethnicity": "African American",
                "statistical representation": "OR (95% CI)",
                "confidence interval": "2.3\u20133.5",
                "p-value": "0.01"
            },
            "measures": "[OR]",
            "outcomes": "[3.1]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "executive function",
                "context": "alcohol use",
                "statistical representation": "OR"
            },
            "measures": "[OR]",
            "outcomes": "[2.6]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "executive function",
                "gender": "females",
                "interaction p-value": "0.35"
            }
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "executive function",
                "gender": "males",
                "interaction p-value": "0.35"
            }
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "executive function",
                "race/ethnicity": "Hispanics",
                "interaction p-value": "0.05"
            }
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "executive function",
                "race/ethnicity": "African American",
                "interaction p-value": "0.05"
            }
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "cognitive flexibility",
                "gender": "females",
                "statistical representation": "OR"
            },
            "measures": "[OR]",
            "outcomes": "[0.9]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "cognitive flexibility",
                "gender": "males",
                "statistical representation": "OR (95% CI)",
                "confidence interval": "1.2\u20132.9",
                "p-value": "0.01"
            },
            "measures": "[OR]",
            "outcomes": "[1.8]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "cognitive flexibility",
                "race/ethnicity": "Hispanics",
                "statistical representation": "OR"
            },
            "measures": "[OR]",
            "outcomes": "[1.9]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "cognitive flexibility",
                "race/ethnicity": "African American",
                "statistical representation": "OR"
            },
            "measures": "[OR]",
            "outcomes": "[1.5]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "cognitive flexibility",
                "context": "alcohol use",
                "statistical representation": "OR (95% CI)",
                "confidence interval": "1.4\u20132.4",
                "p-value": "0.03"
            },
            "measures": "[OR]",
            "outcomes": "[1.6]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "cognitive flexibility",
                "gender": "females",
                "interaction p-value": "0.013"
            }
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "cognitive flexibility",
                "gender": "males",
                "interaction p-value": "0.013"
            }
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "cognitive flexibility",
                "race/ethnicity": "Hispanics",
                "interaction p-value": "0.72"
            }
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "cognitive flexibility",
                "race/ethnicity": "African American",
                "interaction p-value": "0.72"
            }
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "variant": "DRD2 rs6277",
                "trait": "cognitive flexibility",
                "context": "alcohol use",
                "interaction p-value": "0.32"
            }
        }
    ],
    "PMC6694514_3": [
        {
            "subject": {
                "trial": "REMoxTB",
                "population": "matched",
                "phase": "enrolment",
                "comparison": "HIV-positive vs HIV-negative patients",
                "grade": "3 or 4",
                "event type": "Adverse Events (AEs)",
                "system organ class (SOC)": "Hepatobiliary disorders",
                "HIV status": "HIV-positive",
                "total events": "12",
                "percentage of total grade 3 or 4 AEs in HIV-positive group": "30.0%"
            },
            "measures": "[total events]",
            "outcomes": "[12]"
        },
        {
            "subject": {
                "trial": "REMoxTB",
                "population": "matched",
                "phase": "enrolment",
                "comparison": "HIV-positive vs HIV-negative patients",
                "grade": "3 or 4",
                "event type": "Adverse Events (AEs)",
                "system organ class (SOC)": "Hepatobiliary disorders",
                "HIV status": "HIV-negative",
                "total events": "15",
                "percentage of total grade 3 or 4 AEs in HIV-negative group": "25.0%"
            },
            "measures": "[total events]",
            "outcomes": "[15]"
        },
        {
            "subject": {
                "trial": "REMoxTB",
                "population": "matched",
                "phase": "enrolment",
                "comparison": "HIV-positive vs HIV-negative patients",
                "grade": "3 or 4",
                "event type": "Adverse Events (AEs)",
                "system organ class (SOC)": "Respiratory and thoracic disorders",
                "HIV status": "HIV-positive",
                "total events": "7",
                "percentage of total grade 3 or 4 AEs in HIV-positive group": "17.5%"
            },
            "measures": "[total events]",
            "outcomes": "[7]"
        },
        {
            "subject": {
                "trial": "REMoxTB",
                "population": "matched",
                "phase": "enrolment",
                "comparison": "HIV-positive vs HIV-negative patients",
                "grade": "3 or 4",
                "event type": "Adverse Events (AEs)",
                "system organ class (SOC)": "Respiratory and thoracic disorders",
                "HIV status": "HIV-negative",
                "total events": "13",
                "percentage of total grade 3 or 4 AEs in HIV-negative group": "21.7%"
            },
            "measures": "[total events]",
            "outcomes": "[13]"
        },
        {
            "subject": {
                "trial": "REMoxTB",
                "population": "matched",
                "phase": "enrolment",
                "comparison": "HIV-positive vs HIV-negative patients",
                "grade": "3 or 4",
                "event type": "Adverse Events (AEs)",
                "system organ class (SOC)": "Blood and lymphatic disorders",
                "HIV status": "HIV-positive",
                "total events": "6",
                "percentage of total grade 3 or 4 AEs in HIV-positive group": "15.0%"
            },
            "measures": "[total events]",
            "outcomes": "[6]"
        },
        {
            "subject": {
                "trial": "REMoxTB",
                "population": "matched",
                "phase": "enrolment",
                "comparison": "HIV-positive vs HIV-negative patients",
                "grade": "3 or 4",
                "event type": "Adverse Events (AEs)",
                "system organ class (SOC)": "Blood and lymphatic disorders",
                "HIV status": "HIV-negative",
                "total events": "10",
                "percentage of total grade 3 or 4 AEs in HIV-negative group": "16.7%"
            },
            "measures": "[total events]",
            "outcomes": "[10]"
        },
        {
            "subject": {
                "trial": "REMoxTB",
                "population": "matched",
                "phase": "enrolment",
                "comparison": "HIV-positive vs HIV-negative patients",
                "grade": "3 or 4",
                "event type": "Adverse Events (AEs)",
                "system organ class (SOC)": "Infections and infestations",
                "HIV status": "HIV-positive",
                "total events": "3",
                "percentage of total grade 3 or 4 AEs in HIV-positive group": "7.5%"
            },
            "measures": "[total events]",
            "outcomes": "[3]"
        },
        {
            "subject": {
                "trial": "REMoxTB",
                "population": "matched",
                "phase": "enrolment",
                "comparison": "HIV-positive vs HIV-negative patients",
                "grade": "3 or 4",
                "event type": "Adverse Events (AEs)",
                "system organ class (SOC)": "Infections and infestations",
                "HIV status": "HIV-negative",
                "total events": "5",
                "percentage of total grade 3 or 4 AEs in HIV-negative group": "8.3%"
            },
            "measures": "[total events]",
            "outcomes": "[5]"
        },
        {
            "subject": {
                "trial": "REMoxTB",
                "population": "matched",
                "phase": "enrolment",
                "comparison": "HIV-positive vs HIV-negative patients",
                "grade": "3 or 4",
                "event type": "Adverse Events (AEs)",
                "system organ class (SOC)": "Metabolism and nutrition disorders",
                "HIV status": "HIV-positive",
                "total events": "3",
                "percentage of total grade 3 or 4 AEs in HIV-positive group": "7.5%"
            },
            "measures": "[total events]",
            "outcomes": "[3]"
        },
        {
            "subject": {
                "trial": "REMoxTB",
                "population": "matched",
                "phase": "enrolment",
                "comparison": "HIV-positive vs HIV-negative patients",
                "grade": "3 or 4",
                "event type": "Adverse Events (AEs)",
                "system organ class (SOC)": "Metabolism and nutrition disorders",
                "HIV status": "HIV-negative",
                "total events": "4",
                "percentage of total grade 3 or 4 AEs in HIV-negative group": "6.7%"
            },
            "measures": "[total events]",
            "outcomes": "[4]"
        },
        {
            "subject": {
                "trial": "REMoxTB",
                "population": "matched",
                "phase": "enrolment",
                "comparison": "HIV-positive vs HIV-negative patients",
                "grade": "3 or 4",
                "event type": "Adverse Events (AEs)",
                "system organ class (SOC)": "Other",
                "HIV status": "HIV-positive",
                "total events": "9",
                "percentage of total grade 3 or 4 AEs in HIV-positive group": "17.5%"
            },
            "measures": "[total events]",
            "outcomes": "[9]"
        },
        {
            "subject": {
                "trial": "REMoxTB",
                "population": "matched",
                "phase": "enrolment",
                "comparison": "HIV-positive vs HIV-negative patients",
                "grade": "3 or 4",
                "event type": "Adverse Events (AEs)",
                "system organ class (SOC)": "Other",
                "HIV status": "HIV-negative",
                "total events": "13",
                "percentage of total grade 3 or 4 AEs in HIV-negative group": "16.7%"
            },
            "measures": "[total events]",
            "outcomes": "[13]"
        }
    ],
    "PMC6937831_2": [
        {
            "subject": {
                "death category": "Non-AIDS-Related Death (NARD)",
                "cause": "Cancer",
                "number of deaths": "6",
                "percentage of deaths": "4%",
                "classification protocol": "CoDe protocol",
                "cancer type": "unrelated to HIV (e.g., lung cancer)"
            },
            "measures": "[metric, outcome]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "death category": "Non-AIDS-Related Death (NARD)",
                "cause": "Other diseases",
                "number of deaths": "10",
                "percentage of deaths": "8%",
                "classification criteria": "CD4 count > 200 cells/mm\u00b2 within 6 months prior to death"
            },
            "measures": "[metric, outcome]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "death category": "Non-AIDS-Related Death (NARD)",
                "cause": "CVD",
                "number of deaths": "12",
                "percentage of deaths": "9%"
            },
            "measures": "[metric, outcome]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "death category": "Non-AIDS-Related Death (NARD)",
                "cause": "Hepatic/liver-related",
                "number of deaths": "34",
                "percentage of deaths": "24%"
            },
            "measures": "[metric, outcome]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "death category": "Non-AIDS-Related Death (NARD)",
                "cause": "External death",
                "number of deaths": "78",
                "percentage of deaths": "55%",
                "definition": "Sudden death including accident, overdose, and suicide"
            },
            "measures": "[metric, outcome]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "death category": "AIDS-Related Death (ARD)",
                "cause": "Other diseases",
                "number of deaths": "2",
                "percentage of deaths": "1%",
                "classification criteria": "CD4 count \u2264 200 cells/mm\u00b2 within 6 months prior to death"
            },
            "measures": "[metric, outcome]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "death category": "AIDS-Related Death (ARD)",
                "cause": "Cancer",
                "number of deaths": "8",
                "percentage of deaths": "3%",
                "classification protocol": "CoDe protocol",
                "cancer type": "AIDS-related cancers (e.g., cervical cancer)"
            },
            "measures": "[metric, outcome]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "death category": "AIDS-Related Death (ARD)",
                "cause": "Opportunistic",
                "number of deaths": "241",
                "percentage of deaths": "96%"
            },
            "measures": "[metric, outcome]",
            "outcomes": "[]"
        }
    ],
    "PMC6949311_1": [
        {
            "subject": {
                "analysis": "demographic data",
                "study population": "HIV-1/AIDS patients",
                "study population size": "N = 500",
                "comparison group": "healthy controls",
                "comparison group size": "N = 500",
                "variable": "gender",
                "gender": "male",
                "percentage": "65.2%",
                "comparison percentage": "63.4%",
                "P value": "0.553"
            }
        },
        {
            "subject": {
                "analysis": "demographic data",
                "study population": "HIV-1/AIDS patients",
                "study population size": "N = 500",
                "comparison group": "healthy controls",
                "comparison group size": "N = 500",
                "variable": "gender",
                "gender": "female",
                "percentage": "34.8%",
                "comparison percentage": "36.6%"
            }
        },
        {
            "subject": {
                "analysis": "demographic data",
                "study population": "HIV-1/AIDS patients",
                "study population size": "N = 500",
                "comparison group": "healthy controls",
                "comparison group size": "N = 500",
                "variable": "mean age \u00b1 SD (years)",
                "mean age \u00b1 SD": "35.4 \u00b1 7.9",
                "comparison mean age \u00b1 SD": "36.2 \u00b1 9.8",
                "P value": "0.180"
            }
        }
    ],
    "PMC8340029_2": [
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "context": "Including study visits with on-site PrEP access",
                "group": "Before access",
                "data representation": "n/person-years",
                "PrEP": "pre-exposure prophylaxis",
                "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[Number of infections/person-years]",
            "outcomes": "[133/2860]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "context": "Including study visits with on-site PrEP access",
                "group": "Before access",
                "data representation": "incidence",
                "PrEP": "pre-exposure prophylaxis",
                "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[Incidence]",
            "outcomes": "[4.65%]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "context": "Including study visits with on-site PrEP access",
                "group": "After access",
                "data representation": "n/person-years",
                "PrEP": "pre-exposure prophylaxis",
                "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[Number of infections/person-years]",
            "outcomes": "[12/556]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "context": "Including study visits with on-site PrEP access",
                "group": "After access",
                "data representation": "incidence",
                "PrEP": "pre-exposure prophylaxis",
                "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[Incidence]",
            "outcomes": "[2.16%]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "context": "Including study visits with on-site PrEP access",
                "group": "After access",
                "data representation": "adjusted incidence rate ratio (95% CI)",
                "PrEP": "pre-exposure prophylaxis",
                "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[Adjusted incidence rate ratio (95% CI), p value]",
            "outcomes": "[0.45 (0.25-0.81), 0.0076]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "context": "Including study visits with on-site PrEP access",
                "group": "After access",
                "data representation": "adjusted incidence rate ratio (95% CI)",
                "PrEP": "pre-exposure prophylaxis",
                "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[Adjusted incidence rate ratio (95% CI), p value]",
            "outcomes": "[0.45 (0.25-0.82), 0.0085]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "context": "180 days before versus 180 days after on-site PrEP access",
                "group": "Before access",
                "data representation": "n/person-years",
                "PrEP": "pre-exposure prophylaxis",
                "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[Number of infections/person-years]",
            "outcomes": "[46/919]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "context": "180 days before versus 180 days after on-site PrEP access",
                "group": "Before access",
                "data representation": "incidence",
                "PrEP": "pre-exposure prophylaxis",
                "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[Incidence]",
            "outcomes": "[5.00%]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "context": "180 days before versus 180 days after on-site PrEP access",
                "group": "After access",
                "data representation": "n/person-years",
                "PrEP": "pre-exposure prophylaxis",
                "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[Number of infections/person-years]",
            "outcomes": "[11/481]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "context": "180 days before versus 180 days after on-site PrEP access",
                "group": "After access",
                "data representation": "incidence",
                "PrEP": "pre-exposure prophylaxis",
                "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[Incidence]",
            "outcomes": "[2.29%]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "context": "180 days before versus 180 days after on-site PrEP access",
                "group": "After access",
                "data representation": "adjusted incidence rate ratio (95% CI)",
                "PrEP": "pre-exposure prophylaxis",
                "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[Adjusted incidence rate ratio (95% CI), p value]",
            "outcomes": "[0.44 (0.23-0.85), 0.015]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "context": "180 days before versus 180 days after on-site PrEP access",
                "group": "After access",
                "data representation": "adjusted incidence rate ratio (95% CI)",
                "PrEP": "pre-exposure prophylaxis",
                "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[Adjusted incidence rate ratio (95% CI), p value]",
            "outcomes": "[0.43 (0.22-0.83), 0.012]"
        }
    ],
    "PMC4731573_1": [
        {
            "subject": {
                "analysis": "Quantification of HIV-1 (P-24) and HIV-2 (P-26) antigens",
                "donor": "No. 1",
                "HIV-1 replication quantitation method": "Alliance HIV-1 p24 Antigen ELISA Kit (Perkin Elmer)",
                "HIV-2 replication quantitation method": "RETRO-TEK SIV p27 Antigen ELISA Kit (ZeptoMetrix)"
            },
            "measures": "[HIV-1 p24 (pg/ml), HIV-2 p26 (pg/ml)]",
            "outcomes": "[1909, 17683.965]"
        },
        {
            "subject": {
                "analysis": "Quantification of HIV-1 (P-24) and HIV-2 (P-26) antigens",
                "donor": "No. 2",
                "HIV-1 replication quantitation method": "Alliance HIV-1 p24 Antigen ELISA Kit (Perkin Elmer)",
                "HIV-2 replication quantitation method": "RETRO-TEK SIV p27 Antigen ELISA Kit (ZeptoMetrix)"
            },
            "measures": "[HIV-1 p24 (pg/ml), HIV-2 p26 (pg/ml)]",
            "outcomes": "[5649, 46071.77]"
        },
        {
            "subject": {
                "analysis": "Quantification of HIV-1 (P-24) and HIV-2 (P-26) antigens",
                "donor": "No. 3",
                "HIV-1 replication quantitation method": "Alliance HIV-1 p24 Antigen ELISA Kit (Perkin Elmer)",
                "HIV-2 replication quantitation method": "RETRO-TEK SIV p27 Antigen ELISA Kit (ZeptoMetrix)"
            },
            "measures": "[HIV-1 p24 (pg/ml), HIV-2 p26 (pg/ml)]",
            "outcomes": "[1803, 41414.58]"
        }
    ],
    "PMC9720390_1": [
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "One PrEP dose",
                "characteristic": "Number of participants"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "Two PrEP doses",
                "characteristic": "Number of participants"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "No PrEP",
                "characteristic": "Number of participants"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "One PrEP dose",
                "characteristic": "Median age (years)"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "Two PrEP doses",
                "characteristic": "Median age (years)"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "No PrEP",
                "characteristic": "Median age (years)"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "One PrEP dose",
                "characteristic": "STI positivity"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "Two PrEP doses",
                "characteristic": "STI positivity"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "No PrEP",
                "characteristic": "STI positivity"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "One PrEP dose",
                "characteristic": "Number of participants"
            },
            "measures": "[Number of participants]",
            "outcomes": "[48]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "Two PrEP doses",
                "characteristic": "Number of participants"
            },
            "measures": "[Number of participants]",
            "outcomes": "[48]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "No PrEP",
                "characteristic": "Number of participants"
            },
            "measures": "[Number of participants]",
            "outcomes": "[16]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "One PrEP dose",
                "characteristic": "Median age (years)"
            },
            "measures": "[Median age (years)]",
            "outcomes": "[19]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "Two PrEP doses",
                "characteristic": "Median age (years)"
            },
            "measures": "[Median age (years)]",
            "outcomes": "[19]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "No PrEP",
                "characteristic": "Median age (years)"
            },
            "measures": "[Median age (years)]",
            "outcomes": "[19]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "One PrEP dose",
                "characteristic": "STI positivity"
            },
            "measures": "[STI positivity]",
            "outcomes": "[2]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "Two PrEP doses",
                "characteristic": "STI positivity"
            },
            "measures": "[STI positivity]",
            "outcomes": "[4]"
        },
        {
            "subject": {
                "study": "Characteristics of study participants by number of PrEP doses",
                "group": "No PrEP",
                "characteristic": "STI positivity"
            },
            "measures": "[STI positivity]",
            "outcomes": "[0]"
        }
    ],
    "PMC11576434_2": [
        {
            "subject": {
                "analysis": "Top ten most highly expressed TJ genes among CHAPS participants",
                "participants": "CHAPS",
                "sample size": "139",
                "gene": "TRAF4",
                "gene name": "TNF receptor associated factor 4",
                "protein": "TRAF4",
                "protein function": "Adaptor protein involved in signal transduction and regulation of immune response, cell proliferation and apoptosis"
            }
        },
        {
            "subject": {
                "analysis": "Top ten most highly expressed TJ genes among CHAPS participants",
                "participants": "CHAPS",
                "sample size": "139",
                "gene": "RAP2B",
                "gene name": "RAP2B, member of RAS oncogene family",
                "protein": "RAP2B",
                "protein function": "Small GTPase involved in regulation of cell junction assembly and cell\u2013cell adhesion"
            }
        },
        {
            "subject": {
                "analysis": "Top ten most highly expressed TJ genes among CHAPS participants",
                "participants": "CHAPS",
                "sample size": "139",
                "gene": "CCND1",
                "gene name": "Cyclin D1",
                "protein": "Cyclin D1",
                "protein function": "Regulates cell cycle progression"
            }
        },
        {
            "subject": {
                "analysis": "Top ten most highly expressed TJ genes among CHAPS participants",
                "participants": "CHAPS",
                "sample size": "139",
                "gene": "NPHP4",
                "gene name": "Nephrocystin 4",
                "protein": "Nephrocystin 4",
                "protein function": "Functions in cilia and cell\u2013cell junctions; disruption leads to defects in epithelial architecture"
            }
        },
        {
            "subject": {
                "analysis": "Top ten most highly expressed TJ genes among CHAPS participants",
                "participants": "CHAPS",
                "sample size": "139",
                "gene": "TJAP1",
                "gene name": "Tight junction associated protein 1",
                "protein": "TJAP1",
                "protein function": "Scaffolding protein at tight junctions, involved in linking membrane proteins to cytoskeleton"
            }
        },
        {
            "subject": {
                "analysis": "Top ten most highly expressed TJ genes among CHAPS participants",
                "participants": "CHAPS",
                "sample size": "139",
                "gene": "ACTB",
                "gene name": "Actin beta",
                "protein": "\u03b2-actin",
                "protein function": "Structural protein involved in cell shape and motility"
            }
        },
        {
            "subject": {
                "analysis": "Top ten most highly expressed TJ genes among CHAPS participants",
                "participants": "CHAPS",
                "sample size": "139",
                "gene": "CRB3",
                "gene name": "Crumbs homolog 3",
                "protein": "CRB3",
                "protein function": "Maintains apical\u2013basal polarity in epithelial cells and tight junction integrity"
            }
        },
        {
            "subject": {
                "analysis": "Top ten most highly expressed TJ genes among CHAPS participants",
                "participants": "CHAPS",
                "sample size": "139",
                "gene": "PRKCZ",
                "gene name": "Protein kinase C zeta",
                "protein": "PKC\u03b6",
                "protein function": "Involved in TJ formation and maintenance via regulation of polarity complex proteins"
            }
        },
        {
            "subject": {
                "analysis": "Top ten most highly expressed TJ genes among CHAPS participants",
                "participants": "CHAPS",
                "sample size": "139",
                "gene": "CDH5",
                "gene name": "Cadherin 5",
                "protein": "VE-cadherin",
                "protein function": "Calcium-dependent adhesion protein involved in endothelial cell\u2013cell adhesion"
            }
        },
        {
            "subject": {
                "analysis": "Top ten most highly expressed TJ genes among CHAPS participants",
                "participants": "CHAPS",
                "sample size": "139",
                "gene": "ATP7B",
                "gene name": "ATPase copper transporting beta",
                "protein": "ATP7B",
                "protein function": "Involved in copper transport and homeostasis; linked to oxidative stress regulation in epithelial cells"
            }
        }
    ],
    "PMC4486388_1": [
        {
            "subject": {
                "study": "Vaccination groups and allocation",
                "group": "1",
                "participants": "10 (9)",
                "HIV-DNA delivery mode": "No electroporation",
                "left arm injection (w 0": "6, 12), 1 inj 100 \u00b5l 0.3 mg DNA",
                "right arm injection (w 0": "6, 12), 1 inj 100 \u00b5l 0.3 mg DNA",
                "left arm IM immunization (w 24 and 40)": "1 inj HIV-MVA 10^8 pfu (1.0 ml)",
                "observation": "after combination of needle-free ZetaJet delivery and electroporation"
            }
        },
        {
            "subject": {
                "study": "Vaccination groups and allocation",
                "group": "2",
                "participants": "2 (2)",
                "HIV-DNA delivery mode": "No electroporation",
                "left arm injection (w 0": "6, 12), 1 inj 100 \u00b5l saline",
                "right arm injection (w 0": "6, 12), 1 inj 100 \u00b5l saline",
                "left arm IM immunization (w 24 and 40)": "1 inj 1.0 ml saline",
                "observation": "after combination of needle-free ZetaJet delivery and electroporation"
            }
        },
        {
            "subject": {
                "study": "Vaccination groups and allocation",
                "group": "2",
                "participants": "10 (7)",
                "HIV-DNA delivery mode": "Electroporation",
                "left arm injection (w 0": "6, 12), 1 inj 100 \u00b5l 0.3 mg DNA",
                "right arm injection (w 0": "6, 12), 1 inj 100 \u00b5l 0.3 mg DNA",
                "left arm IM immunization (w 24 and 40)": "1 inj HIV-MVA 10^8 pfu",
                "observation": "after combination of needle-free ZetaJet delivery and electroporation"
            }
        }
    ],
    "PMC8391097_3": [
        {
            "subject": {
                "analysis": "HIV Incidence Rate Estimates",
                "group": "Overall",
                "HIV infections": "No./total No. of individuals, 91/13 861",
                "total follow-up": "person-years, 26 210",
                "incidence": "per 100 person-years, 0.35 (0.28-0.43)",
                "exclusion criteria": "Excludes individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage"
            },
            "measures": "[incidence rate]",
            "outcomes": "[0.35 (0.28-0.43)]"
        },
        {
            "subject": {
                "analysis": "HIV Incidence Rate Estimates",
                "group": "Linked but not prescribed PrEP",
                "HIV infections": "No./total No. of individuals, 36/3013",
                "total follow-up": "person-years, 4119",
                "incidence": "per 100 person-years, 0.87 (0.63-1.21)"
            },
            "measures": "[incidence rate]",
            "outcomes": "[0.87 (0.63-1.21)]"
        },
        {
            "subject": {
                "analysis": "HIV Incidence Rate Estimates",
                "group": "Prescribed PrEP but did not initiate",
                "HIV infections": "No./total No. of individuals, 13/811",
                "total follow-up": "person-years, 1226",
                "incidence": "per 100 person-years, 1.06 (0.62-1.83)"
            },
            "measures": "[incidence rate]",
            "outcomes": "[1.06 (0.62-1.83)]"
        },
        {
            "subject": {
                "analysis": "HIV Incidence Rate Estimates",
                "group": "Discontinued but reinitiated PrEP",
                "HIV infections": "No./total No. of individuals, 4/1082",
                "total follow-up": "person-years, 1420",
                "incidence": "per 100 person-years, 0.28 (0.11-0.75)"
            },
            "measures": "[incidence rate]",
            "outcomes": "[0.28 (0.11-0.75)]"
        },
        {
            "subject": {
                "analysis": "HIV Incidence Rate Estimates",
                "group": "Discontinued and did not reinitiate PrEP",
                "HIV infections": "No./total No. of individuals, 38/2108",
                "total follow-up": "person-years, 2973",
                "incidence": "per 100 person-years, 1.28 (0.93-1.76)"
            },
            "measures": "[incidence rate]",
            "outcomes": "[1.28 (0.93-1.76)]"
        },
        {
            "subject": {
                "analysis": "HIV Incidence Rate Estimates",
                "group": "Persistent on PrEP",
                "HIV infections": "No./total No. of individuals, 0/5367",
                "total follow-up": "person-years, 9139",
                "incidence": "per 100 person-years, 0.00 (0.00-0.04)",
                "definition": "Persistent on PrEP refers to individuals who initiated and remained on PrEP throughout follow-up",
                "confidence interval": "One-sided 97.5% upper CI"
            },
            "measures": "[incidence rate]",
            "outcomes": "[0.00 (0.00-0.04)]"
        }
    ],
    "PMC4358901_1": [
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-1",
                "group": "M",
                "subtype/CRF": "A1",
                "number of genomes": "159",
                "number of patients": "134",
                "average length in nucleotides": "8500",
                "data alignment": "based on the aligned data set"
            }
        },
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-1",
                "group": "M",
                "subtype/CRF": "B",
                "number of genomes": "1425",
                "number of patients": "657",
                "average length in nucleotides": "8600",
                "data alignment": "based on the aligned data set"
            }
        },
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-1",
                "group": "M",
                "subtype/CRF": "C",
                "number of genomes": "554",
                "number of patients": "429",
                "average length in nucleotides": "8600",
                "data alignment": "based on the aligned data set"
            }
        },
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-1",
                "group": "M",
                "subtype/CRF": "D",
                "number of genomes": "65",
                "number of patients": "57",
                "average length in nucleotides": "8500",
                "data alignment": "based on the aligned data set"
            }
        },
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-1",
                "group": "M",
                "subtype/CRF": "F1",
                "number of genomes": "25",
                "number of patients": "22",
                "average length in nucleotides": "8500",
                "data alignment": "based on the aligned data set"
            }
        },
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-1",
                "group": "M",
                "subtype/CRF": "G",
                "number of genomes": "27",
                "number of patients": "23",
                "average length in nucleotides": "8600",
                "data alignment": "based on the aligned data set"
            }
        },
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-1",
                "group": "M",
                "subtype/CRF": "H",
                "number of genomes": "4",
                "number of patients": "4",
                "average length in nucleotides": "8500",
                "data alignment": "based on the aligned data set"
            }
        },
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-1",
                "group": "M",
                "subtype/CRF": "J",
                "number of genomes": "2",
                "number of patients": "2",
                "average length in nucleotides": "8500",
                "data alignment": "based on the aligned data set"
            }
        },
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-1",
                "group": "M",
                "subtype/CRF": "K",
                "number of genomes": "2",
                "number of patients": "2",
                "average length in nucleotides": "8500",
                "data alignment": "based on the aligned data set"
            }
        },
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-1",
                "group": "M",
                "subtype/CRF": "01_AE",
                "number of genomes": "581",
                "number of patients": "250",
                "average length in nucleotides": "8600",
                "data alignment": "based on the aligned data set"
            }
        },
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-1",
                "group": "M",
                "subtype/CRF": "02_AG",
                "number of genomes": "81",
                "number of patients": "71",
                "average length in nucleotides": "8600",
                "data alignment": "based on the aligned data set"
            }
        },
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-1",
                "group": "N",
                "number of genomes": "11",
                "number of patients": "9",
                "average length in nucleotides": "8600",
                "data alignment": "based on the aligned data set"
            }
        },
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-1",
                "group": "O",
                "number of genomes": "25",
                "number of patients": "22",
                "average length in nucleotides": "8600",
                "data alignment": "based on the aligned data set"
            }
        },
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-1",
                "group": "P",
                "number of genomes": "4",
                "number of patients": "2",
                "average length in nucleotides": "8500",
                "data alignment": "based on the aligned data set"
            }
        },
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-2",
                "group": "A",
                "number of genomes": "25",
                "number of patients": "16",
                "average length in nucleotides": "8600",
                "data alignment": "based on the aligned data set"
            }
        },
        {
            "subject": {
                "study": "HIV-1 and HIV-2 full-length genome data sets",
                "type": "HIV-2",
                "group": "B",
                "number of genomes": "6",
                "number of patients": "5",
                "average length in nucleotides": "8500",
                "data alignment": "based on the aligned data set"
            }
        }
    ],
    "PMC8748440_2": [
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "ISG15",
                "HR (hazard ratio)": "0.29",
                "95% CI for HR": "0.11\u20130.81",
                "p value": "0.0091",
                "module": "salmon Module 1",
                "selection criteria": "p < 0.05"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.29, 0.0091]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "IFI6",
                "HR (hazard ratio)": "0.18",
                "95% CI for HR": "0.037\u20130.86",
                "p value": "0.014",
                "module": "salmon Module 1",
                "selection criteria": "p < 0.05"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.18, 0.014]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "IFI44L",
                "HR (hazard ratio)": "0.55",
                "95% CI for HR": "0.27\u20131.1",
                "p value": "0.083",
                "module": "salmon Module 1"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.55, 0.083]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "IFI44",
                "HR (hazard ratio)": "0.23",
                "95% CI for HR": "0.047\u20131.2",
                "p value": "0.045",
                "module": "salmon Module 1",
                "selection criteria": "p < 0.05"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.23, 0.045]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "IFIT1",
                "HR (hazard ratio)": "0.37",
                "95% CI for HR": "0.12\u20131.1",
                "p value": "0.054",
                "module": "salmon Module 1"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.37, 0.054]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "OAS3",
                "HR (hazard ratio)": "0.52",
                "95% CI for HR": "0.22\u20131.3",
                "p value": "0.15",
                "module": "salmon Module 1"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.52, 0.15]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "XAF1",
                "HR (hazard ratio)": "0.3",
                "95% CI for HR": "0.1\u20130.92",
                "p value": "0.027",
                "module": "salmon Module 1",
                "selection criteria": "p < 0.05"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.3, 0.027]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "TRIM25",
                "HR (hazard ratio)": "0.074",
                "95% CI for HR": "0.0068\u20130.8",
                "p value": "0.023",
                "module": "salmon Module 1",
                "selection criteria": "p < 0.05"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.074, 0.023]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "CMPK2",
                "HR (hazard ratio)": "0.23",
                "95% CI for HR": "0.037\u20131.5",
                "p value": "0.074",
                "module": "salmon Module 1"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.23, 0.074]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "RSAD2",
                "HR (hazard ratio)": "0.2",
                "95% CI for HR": "0.041\u20130.99",
                "p value": "0.032",
                "module": "salmon Module 1",
                "selection criteria": "p < 0.05"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.2, 0.032]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "EIF2AK2",
                "HR (hazard ratio)": "0.54",
                "95% CI for HR": "0.12\u20132.4",
                "p value": "0.42",
                "module": "salmon Module 1"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.54, 0.42]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "USP18",
                "HR (hazard ratio)": "0.23",
                "95% CI for HR": "0.062\u20130.84",
                "p value": "0.022",
                "module": "salmon Module 1",
                "selection criteria": "p < 0.05"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.23, 0.022]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "HERC6",
                "HR (hazard ratio)": "0.16",
                "95% CI for HR": "0.019\u20131.3",
                "p value": "0.057",
                "module": "salmon Module 1"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.16, 0.057]"
        }
    ],
    "PMC7615197_2": [
        {
            "subject": {
                "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                "population": "Intention-to-treat population",
                "treatment arm": "dexamethasone",
                "control arm": "placebo",
                "total participants in treatment arm": "263",
                "total participants in control arm": "257",
                "primary endpoint": "death from any cause over the first 12 months after randomization",
                "time frame": "first 12 months of follow-up",
                "statistical model": "Cox proportional hazards regression model",
                "effect measure": "hazard ratio",
                "confidence interval": "95%",
                "P-value": "0.22",
                "test for proportional hazards": "Kaplan-Meier as time transformation"
            },
            "measures": "[hazard ratio (95% CI), P-value]",
            "outcomes": "[0.85 (0.66, 1.10), 0.22]"
        },
        {
            "subject": {
                "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                "population": "Intention-to-treat population",
                "treatment arm": "dexamethasone",
                "control arm": "placebo",
                "total participants in treatment arm": "263",
                "total participants in control arm": "257",
                "primary endpoint": "death from any cause over the first 12 months after randomization",
                "time frame": "first 12 months of follow-up",
                "statistical model": "Cox proportional hazards regression model",
                "effect measure": "hazard ratio",
                "confidence interval": "95%",
                "P-value": "0.22",
                "test for proportional hazards": "Kaplan-Meier as time transformation",
                "deaths in treatment arm": "116/263",
                "deaths in control arm": "126/257"
            },
            "measures": "[hazard ratio (95% CI), P-value]",
            "outcomes": "[0.85 (0.66, 1.10), 0.22]"
        },
        {
            "subject": {
                "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                "population": "Modified MRC grade",
                "subgroup": "Grade I",
                "treatment arm": "dexamethasone",
                "control arm": "placebo",
                "total participants in treatment arm": "99",
                "total participants in control arm": "97",
                "primary endpoint": "death from any cause over the first 12 months after randomization",
                "time frame": "first 12 months of follow-up",
                "statistical model": "Cox proportional hazards regression model",
                "effect measure": "hazard ratio",
                "confidence interval": "95%",
                "P-value": "0.24",
                "test for proportional hazards": "Kaplan-Meier as time transformation",
                "heterogeneity P-value": "0.63",
                "deaths in treatment arm": "22/99",
                "deaths in control arm": "28/97"
            },
            "measures": "[hazard ratio (95% CI), P-value]",
            "outcomes": "[0.72 (0.41, 1.25), 0.24]"
        },
        {
            "subject": {
                "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                "population": "Modified MRC grade",
                "subgroup": "Grade II",
                "treatment arm": "dexamethasone",
                "control arm": "placebo",
                "total participants in treatment arm": "125",
                "total participants in control arm": "126",
                "primary endpoint": "death from any cause over the first 12 months after randomization",
                "time frame": "first 12 months of follow-up",
                "statistical model": "Cox proportional hazards regression model",
                "effect measure": "hazard ratio",
                "confidence interval": "95%",
                "P-value": "0.27",
                "test for proportional hazards": "Kaplan-Meier as time transformation",
                "heterogeneity P-value": "0.63",
                "deaths in treatment arm": "60/125",
                "deaths in control arm": "68/126"
            },
            "measures": "[hazard ratio (95% CI), P-value]",
            "outcomes": "[0.82 (0.58, 1.16), 0.27]"
        },
        {
            "subject": {
                "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                "population": "Modified MRC grade",
                "subgroup": "Grade III",
                "treatment arm": "dexamethasone",
                "control arm": "placebo",
                "total participants in treatment arm": "39",
                "total participants in control arm": "34",
                "primary endpoint": "death from any cause over the first 12 months after randomization",
                "time frame": "first 12 months of follow-up",
                "statistical model": "Cox proportional hazards regression model",
                "effect measure": "hazard ratio",
                "confidence interval": "95%",
                "P-value": "0.65",
                "test for proportional hazards": "Kaplan-Meier as time transformation",
                "heterogeneity P-value": "0.63",
                "deaths in treatment arm": "34/39",
                "deaths in control arm": "30/34"
            },
            "measures": "[hazard ratio (95% CI), P-value]",
            "outcomes": "[1.11 (0.70, 1.77), 0.65]"
        }
    ],
    "PMC9008168_2": [
        {
            "subject": {
                "analysis": "Unadjusted incidence rates and hazard ratios (HR) of BMI \u226525 kg/m\u00b2 by HIV and ART status",
                "population": "Participants without HIV",
                "incidence rate (cases/1000 PY)": "69.8",
                "95% CI for incidence rate": "54.7\u201389.0",
                "HR": "1.00",
                "95% CI for HR": "Reference",
                "condition": "BMI \u226525 kg/m\u00b2",
                "study population": "2144 participants at risk",
                "developed condition": "516 participants",
                "abbreviation": "PY (person-years)"
            },
            "measures": "[incidence rate, HR]",
            "outcomes": "[69.8, 1.00]"
        },
        {
            "subject": {
                "analysis": "Unadjusted incidence rates and hazard ratios (HR) of BMI \u226525 kg/m\u00b2 by HIV and ART status",
                "population": "PLWH on non-TLD ART",
                "incidence rate (cases/1000 PY)": "77.1",
                "95% CI for incidence rate": "69.8\u201385.2",
                "HR": "1.13",
                "95% CI for HR": "0.79\u20131.63",
                "condition": "BMI \u226525 kg/m\u00b2",
                "study population": "2144 participants at risk",
                "developed condition": "516 participants",
                "abbreviation": "PY (person-years)"
            },
            "measures": "[incidence rate, HR]",
            "outcomes": "[77.1, 1.13]"
        },
        {
            "subject": {
                "analysis": "Unadjusted incidence rates and hazard ratios (HR) of BMI \u226525 kg/m\u00b2 by HIV and ART status",
                "population": "PLWH on TLD",
                "incidence rate (cases/1000 PY)": "73.3",
                "95% CI for incidence rate": "54.0\u201399.6",
                "HR": "1.77",
                "95% CI for HR": "1.22\u20132.55",
                "condition": "BMI \u226525 kg/m\u00b2",
                "study population": "2144 participants at risk",
                "developed condition": "516 participants",
                "abbreviation": "PY (person-years)"
            },
            "measures": "[incidence rate, HR]",
            "outcomes": "[73.3, 1.77]"
        },
        {
            "subject": {
                "analysis": "Unadjusted incidence rates and hazard ratios (HR) of BMI \u226525 kg/m\u00b2 by HIV and ART status",
                "population": "PLWH, ART na\u00efve",
                "incidence rate (cases/1000 PY)": "37.7",
                "95% CI for incidence rate": "24.1\u201359.1",
                "HR": "0.43",
                "95% CI for HR": "0.27\u20130.70",
                "condition": "BMI \u226525 kg/m\u00b2",
                "study population": "2144 participants at risk",
                "developed condition": "516 participants",
                "abbreviation": "PY (person-years)"
            },
            "measures": "[incidence rate, HR]",
            "outcomes": "[37.7, 0.43]"
        }
    ],
    "PMC10022814_1": [
        {
            "subject": {
                "design": "All-comers design",
                "primary objective": "Evaluate VE in population not on stable PrEP",
                "key secondary objectives": "1. Evaluate VE among those not on PrEP at acquisition",
                "footnote a": "Addressed using retrospective assaying of stored blood to test for ARV drug levels",
                "footnote b": "Evaluable if designs continue to follow and collect HIV endpoint data on individuals who remain interested and adherent to PrEP after each run-in period"
            }
        },
        {
            "subject": {
                "design": "1-Stage Run-In Design",
                "primary objective": "Evaluate VE in population declining or not adherent to PrEP at screening or after 1 stage of PrEP",
                "key secondary objectives": "1. Evaluate VE among those not on PrEP at acquisition; 2. Evaluate PrEP effectiveness (PrEP vs. Placebo); 3. Compare Vaccine vs. PrEP effectiveness",
                "footnote a": "Addressed using retrospective assaying of stored blood to test for ARV drug levels",
                "footnote b": "Evaluable if designs continue to follow and collect HIV endpoint data on individuals who remain interested and adherent to PrEP after each run-in period"
            }
        },
        {
            "subject": {
                "design": "3-Stage Run-In Design",
                "primary objective": "Evaluate VE in population declining or not adherent to PrEP at screening or after 1, 2, or 3 stages of PrEP",
                "key secondary objectives": "1. Evaluate VE among those not on PrEP at acquisition; 2. Evaluate PrEP effectiveness (PrEP vs. Placebo); 3. Compare Vaccine vs. PrEP effectiveness",
                "footnote a": "Addressed using retrospective assaying of stored blood to test for ARV drug levels",
                "footnote b": "Evaluable if designs continue to follow and collect HIV endpoint data on individuals who remain interested and adherent to PrEP after each run-in period"
            }
        },
        {
            "subject": {
                "design": "Decliners Design",
                "primary objective": "Evaluate VE in population declining PrEP at screening",
                "key secondary objectives": "1. Evaluate VE among those not on PrEP at acquisition",
                "footnote a": "Addressed using retrospective assaying of stored blood to test for ARV drug levels",
                "footnote b": "Evaluable if designs continue to follow and collect HIV endpoint data on individuals who remain interested and adherent to PrEP after each run-in period"
            }
        }
    ],
    "PMC6033411_2": [
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "Age (years)",
                "age group": "15 and younger",
                "total participants": "69 (34.5%)",
                "clustered participants": "22 (37.3%)",
                "odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "Age (years)",
                "age group": "16",
                "total participants": "46 (23%)",
                "clustered participants": "13 (22%)",
                "odds ratio": "0.84 (0.36\u20131.89)",
                "P-value": "0.67"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "Age (years)",
                "age group": "17+",
                "total participants": "85 (42.5%)",
                "clustered participants": "24 (40.7%)",
                "odds ratio": "0.87 (0.43\u20131.76)",
                "P-value": "0.69"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "School grade",
                "grade group": "8\u20139",
                "total participants": "90 (45%)",
                "clustered participants": "30 (50.8%)",
                "odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "School grade",
                "grade group": "10\u201312",
                "total participants": "110 (55%)",
                "clustered participants": "29 (49.2%)",
                "odds ratio": "0.8 (0.43\u20131.52)",
                "P-value": "0.5"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "Household income (R)",
                "income group": "<999",
                "total participants": "61 (30.5%)",
                "clustered participants": "22 (37.3%)",
                "odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "Household income (R)",
                "income group": "10,000\u201399,000",
                "total participants": "112 (56%)",
                "clustered participants": "27 (45.8%)",
                "odds ratio": "0.56 (0.29\u20131.11)",
                "P-value": "0.1"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "Household income (R)",
                "income group": ">100,000",
                "total participants": "27 (12.5%)",
                "clustered participants": "10 (16.9%)",
                "odds ratio": "1.04 (0.39\u20132.65)",
                "P-value": "0.93"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "CD4 cell count, cells/mm\u00b3",
                "CD4 group": ">500",
                "total participants": "92 (46%)",
                "clustered participants": "30 (50.9%)",
                "odds ratio": "1.0 (ref)",
                "P-value": "\u2026",
                "footnote": "CD4 cell count data was not available for 18 women"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "CD4 cell count, cells/mm\u00b3",
                "CD4 group": "\u2264500",
                "total participants": "75 (37.5%)",
                "clustered participants": "19 (32.2%)",
                "odds ratio": "0.70 (0.35\u20131.37)",
                "P-value": "0.31",
                "footnote": "CD4 cell count data was not available for 18 women"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "CD4 cell count, cells/mm\u00b3",
                "CD4 group": "\u2264250",
                "total participants": "15 (7.5%)",
                "clustered participants": "4 (6.8%)",
                "odds ratio": "0.75 (0.2\u20132.4)",
                "P-value": "0.65",
                "footnote": "CD4 cell count data was not available for 18 women"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "Major drug resistance mutation",
                "mutation status": "No",
                "total participants": "180 (90%)",
                "clustered participants": "55 (93.2)",
                "odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "Major drug resistance mutation",
                "mutation status": "Yes",
                "total participants": "20 (10%)",
                "clustered participants": "4 (6.8%)",
                "odds ratio": "0.57 (0.16\u20131.63)",
                "P-value": "0.33"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "HSV-2 infection",
                "infection status": "No",
                "total participants": "90 (45%)",
                "clustered participants": "25 (42.4%)",
                "odds ratio": "1.0 (ref)",
                "P-value": "\u2026",
                "footnote": "HSV-2 infection status was not available for 41 women"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "HSV-2 infection",
                "infection status": "Yes",
                "total participants": "69 (34.5%)",
                "clustered participants": "23 (39%)",
                "odds ratio": "1.3 (0.65\u20132.57)",
                "P-value": "0.45",
                "footnote": "HSV-2 infection status was not available for 41 women"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "Ever pregnant",
                "pregnancy status": "No",
                "total participants": "122 (61%)",
                "clustered participants": "37 (62.7%)",
                "odds ratio": "1.0 (ref)",
                "P-value": "\u2026",
                "footnote": "Pregnancy history was not available for 29 women"
            }
        },
        {
            "subject": {
                "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                "threshold": "4.5% genetic distance",
                "characteristic": "Ever pregnant",
                "pregnancy status": "Yes",
                "total participants": "49 (24.5%)",
                "clustered participants": "15 (25.4%)",
                "odds ratio": "1.01 (0.48\u20132.06)",
                "P-value": "0.971",
                "footnote": "Pregnancy history was not available for 29 women"
            }
        }
    ]
}